Production (Stage)
Lexeo Therapeutics, Inc.
LXEO
$3.88
$0.6118.65%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -6.51% | -21.59% | |||
| Gross Profit | 6.51% | 21.59% | |||
| SG&A Expenses | 84.49% | 11.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.46% | -13.19% | |||
| Operating Income | -23.46% | 13.19% | |||
| Income Before Tax | -25.97% | 12.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -25.97% | 12.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.97% | 12.09% | |||
| EBIT | -23.46% | 13.19% | |||
| EBITDA | -23.65% | 13.23% | |||
| EPS Basic | -25.82% | 12.12% | |||
| Normalized Basic EPS | -25.66% | 12.04% | |||
| EPS Diluted | -25.82% | 12.12% | |||
| Normalized Diluted EPS | -25.66% | 12.04% | |||
| Average Basic Shares Outstanding | 0.11% | 0.04% | |||
| Average Diluted Shares Outstanding | 0.11% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||